Published in Clin Cancer Res on November 01, 1997
Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs (1999) 0.94
Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies. Invest New Drugs (2008) 0.78
Modulation of dendritic cell function by the radiation-mediated secretory protein γ-synuclein. Cell Death Discov (2015) 0.77
Cryptophycin 1 cellular levels and effects in vitro using L1210 cells. Invest New Drugs (1999) 0.75
A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet (1995) 3.93
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet (1993) 3.08
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res (1984) 2.74
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res (1975) 2.54
Mumps meningitis and measles, mumps, and rubella vaccine. Lancet (1992) 2.30
Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J Am Chem Soc (2001) 2.06
Birth defects among children of nurse-anesthetists. Anesthesiology (1974) 2.04
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer (2011) 1.99
Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod (2001) 1.75
A survey of anesthetic health hazards among dentists. J Am Dent Assoc (1975) 1.70
Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet (1987) 1.54
Toxicity of polybrominated biphenyls Firemaster BP-6 in rodents. Environ Res (1975) 1.53
Incidence of cancer among Michigan nurse-anesthetists. Anesthesiology (1973) 1.51
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep (1980) 1.47
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs (1986) 1.41
Nitrous oxide concentrations in the dental operatory. J Oral Surg (1974) 1.40
Multilocus markers for mouse genome analysis: PCR amplification based on single primers of arbitrary nucleotide sequence. Mamm Genome (1992) 1.36
Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat (2006) 1.28
Validation of beat by beat pulsed Doppler measurements of ascending aortic blood velocity in man. Cardiovasc Res (1987) 1.23
Who is being tested for genital chlamydia in primary care? Sex Transm Infect (2003) 1.23
Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res (1996) 1.22
Isolation and cytotoxic evaluation of marine sponge-derived norterpene peroxides. J Nat Prod (1998) 1.21
In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res (1982) 1.18
Establishment of cross-resistance profiles for new agents. Cancer Treat Rep (1983) 1.18
Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res (1988) 1.18
Relation of human cardiac action potential duration to the interval between beats: implications for the validity of rate corrected QT interval (QTc). Br Heart J (1987) 1.17
A colon tumor model for anticancer agent evaluation. Cancer (1975) 1.17
Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages. J Nat Prod (1998) 1.15
Targeting the epidermal growth factor receptor. Br J Cancer (2004) 1.14
Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs (1997) 1.12
Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs (2001) 1.10
Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep (1978) 1.09
Specialized gastrointestinal units for the management of upper gastrointestinal haemorrhage. Postgrad Med J (1990) 1.08
Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod (1998) 1.07
Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer (1977) 1.06
The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways. Clin Cancer Res (2001) 1.02
Determination of the mutagenic activity to bacteriophage T4 of carcinogenic and noncarcinogenic compounds. Mol Pharmacol (1970) 1.02
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs (1997) 1.02
Retention of anesthetic agents following occupational exposure. Anesth Analg (1973) 1.02
Methylene-gem-difluorocyclopropane analogues of nucleosides: synthesis, cyclopropene-methylenecyclopropane rearrangement, and biological activity. J Med Chem (2001) 1.01
Preclinical antitumor activity of XK469 (NSC 656889). Invest New Drugs (1999) 1.01
Effects of low concentrations of nitrous oxide on rat pregnancy. Anesthesiology (1973) 1.00
Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs (1987) 0.99
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res (1990) 0.98
In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia. Proc Natl Acad Sci U S A (1983) 0.97
Retinoic acid-binding protein in normal tissues and experimental tumors. Cancer Res (1977) 0.96
Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Invest New Drugs (1998) 0.96
A test of the carcinogenicity of enflurane, isoflurane, halothane, methoxyflurane, and nitrous oxide in mice. Anesth Analg (1979) 0.96
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. Bone Marrow Transplant (2012) 0.95
Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs (1999) 0.94
Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res (1975) 0.93
Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. Cancer Res (1987) 0.93
Chronic exposure to methoxyflurane: a possible occupational hazard to anesthesiologists. Anesthesiology (1971) 0.92
Cancer and congenital anomalies associated with anesthetics. Ann N Y Acad Sci (1976) 0.92
Retarded habituation and lateral asymmetries in electrodermal activity in cardiovascular disorders. Int J Psychophysiol (1986) 0.92
Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res (1982) 0.91
HLA-D region antigen expression on stomach epithelium in absence of autoantibodies. Lancet (1986) 0.91
Rapid detection and serotyping of adenovirus by direct immunofluorescence. J Med Virol (1997) 0.90
New murine polymorphisms detected by random amplified polymorphic DNA (RAPD) PCR and mapped by use of recombinant inbred strains. Mamm Genome (1994) 0.90
Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. Cancer Chemother Pharmacol (1989) 0.90
Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo. Cancer Res (1988) 0.89
Anesthetics as a cause of abortion. Fertil Steril (1972) 0.89
Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther (2007) 0.88
Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res (2000) 0.88
Which peptic ulcer patients bleed? Gut (1988) 0.88
Propofol infusion for the treatment of status epilepticus. Lancet (1988) 0.87
Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). Invest New Drugs (1997) 0.87
Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiol Infect (2006) 0.86
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). J Med Chem (2001) 0.86
Activity of batracylin (NSC-320846) against solid tumors of mice. Invest New Drugs (1989) 0.86
Levels of 5-hydroxymethyl-2'-deoxyuridine in DNA from blood as a marker of breast cancer. Cancer (1996) 0.85
In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. J Natl Cancer Inst (1994) 0.85
Correlation of antibiotic usage with an antibiotic policy in a urological ward. J Hosp Infect (1981) 0.85
Antibiotic therapy, clinical features and outcome of 36 adults presenting to hospital with proven influenza: do we follow guidelines? Postgrad Med J (1991) 0.84
Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep (1982) 0.84
Hemodynamic response to treadmill exercise in normal volunteers: an assessment by Doppler ultrasonic measurement of ascending aortic blood velocity and acceleration. Am Heart J (1988) 0.83
Human tumors as examined by in vivo 31P NMR in athymic mice. Biochem Biophys Res Commun (1982) 0.82
Medical audit and formulary management: a policy for rational use of thrombolytic drugs. Postgrad Med J (1991) 0.82
Pharmacology and toxicology of halogenated anesthetics. Adv Pharmacol Chemother (1979) 0.82
Poisoning with oxybutynin. Hum Exp Toxicol (1991) 0.82
Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer (1984) 0.81
Hepatitis B immunization in vascular surgeons. Br J Surg (1990) 0.81
Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rep (1979) 0.81
Problem of measuring the positive inotropic property of a vasodilating drug: an illustration using felodipine. Cardiovasc Res (1987) 0.81
Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03. J Med Chem (1994) 0.81
Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools. Cancer Res (1992) 0.80
Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol Ther (1983) 0.80
Tumor cell growth inhibition by several Annonaceous acetogenins in an in vitro disk diffusion assay. Cancer Lett (1995) 0.80
High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma. J Chromatogr B Biomed Sci Appl (2001) 0.80
Effect of PR-8 viral respiratory infection of benz[a]pyrene hydroxylase activity in BALB/c mice. J Natl Cancer Inst (1973) 0.79
Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemother Pharmacol (1981) 0.79
Rapid diagnosis of cytomegalovirus infection by detection of early antigen fluorescent foci. Lancet (1987) 0.79